Clinical, Histological, and Molecular Features of Solitary Fibrous Tumor of Bone: A Single Institution Retrospective Review

Giuseppe Bianchi 1, Debora Lana 1, Marco Gambarotti 2, Cristina Ferrari 3, Marta Sbaraglia 4, Elena Pedrini 5, Laura Pazzaglia 3, Luca Sangiorgi 5, Isabella Bartolotti 5, Angelo Paolo Dei Tos 6, Katia Scotlandi 3 and Alberto Righi 2,*

1 Department of Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; giuseppe.bianchi@ior.it (G.B.); debora.lana88@gmail.com (D.L.)
2 Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; marco.gambarotti@ior.it
3 Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; cristina.ferrari@ior.it (C.F.); laura.pazzaglia@ior.it (L.P.); katia.scotlandi@ior.it (K.S.)
4 Department of Pathology, Azienda Ospedaliera di Padova, 35121 Padua, Italy; marta.sbaraglia@aopd.veneto.it
5 Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; elena.pedrini@ior.it (E.P.); luca.sangiorgi@ior.it (L.S.); isabella.bartolotti@ior.it (I.B.)
6 Department of Medicine, University of Padua School of Medicine, 35121 Padua, Italy; angelo.deitos@unipd.it

* Correspondence: alberto.righi@ior.it; Tel.: +39-051-636-6665

Simple Summary: Solitary fibrous tumors arising from the bone are an extremely rare event and only few cases have been previously described in the literature. It is characterized by a prominent, branched vascularization, with a thin and dilated vascular texture defined as “staghorn” and by the presence of the NAB2-STAT6 gene rearrangement, present in about 90% of cases and considered a pathognomonic feature. In the present study, we described our series of 24 cases of primary solitary fibrous tumor of the bone to find any clinical and molecular prognostic factors and to compare them with those currently used for soft tissue solitary fibrous tumor and to evaluate the risk stratification system proposed by Demicco, in order to understand whether this system was able to correctly predict the risk of local and distant metastatic relapse even in the case of solitary fibrous tumor of the bone.

Abstract: Primary solitary fibrous tumor (SFT) of the bone is extremely rare, with only few cases reported in the literature. We retrieved all cases of primary SFT of the bone treated at our institution and we assessed the morphology and the immunohistochemical and molecular features to investigate the clinical outcome of primary SFT of the bone and any clinical relevance of clinical and histological criteria of aggressiveness currently adopted for the soft tissues counterpart. Morphologically, 15 cases evidenced high cellularity, cytologic atypia, and foci of necrosis and were associated with more than 4 mitotic figures/10 HPF. Immunohistochemical analysis showed an expression of CD34 and of STAT6 immunopositivity in 95% and in 100% of cases, respectively. The presence of NAB2-STAT6 chimeric transcripts was found in 10 out of 12 cases in which RT-PCR analysis was feasible, whereas TERT promoter mutations analysis was feasible in 16 cases and only a C-to-T substitution in a heterozygous state was found in one DNA sample for the C228T genetic variant. P53 variants were assessed in 12 cases: 11 (91.6%) cases showed a variation, while in one case, no alteration was found. Disease-specific survival was 64% at 5 years and 49% at 10 years. Statistical analysis showed no correlation between survival and all the clinicopathological and molecular parameters evaluated. In conclusion, at difference to SFT of soft tissues, aggressive behavior of primary SFT of the bone seems to be independent from mitotic count or any other clinicopathological and molecular features.

Keywords: solitary fibrous tumor; primary bone tumor; risk stratification; prognosis; NAB2-STAT6 fusion transcripts
1. Introduction

Solitary fibrous tumor (SFT) is a rare mesenchymal tumor of fibroblastic origin that can occur at any anatomic site and typically affects middle-aged adults [1–3]. It is characterized by a strong morphologic heterogeneity with a wide spectrum of biologic features. The histological and molecular diagnostic criteria used in soft tissue SFT (S-SFT) have been recently applied on “non otherwise classified” primary bone tumors, drawing out a new category of SFT of the bone (B-SFT) [4–7]. Nevertheless, B-SFT is exceedingly rare, with only few cases are described in the literature [8–11], and its biological behavior has not yet been assessed. From a histopathological and molecular point of view, primary B-SFT shares the same features of S-SFT. It is characterized by a prominent, branched vascularization, with a thin and dilated vascular texture defined as “staghorn” and by the presence of the NAB2-STAT6 gene rearrangement (NGFI-A binding protein 2—Signal Transducer and Activator of Transcription 6), present in about 90% of cases and considered a pathognomonic feature [1,12]. Positivity to CD34 stain is distinctive in 90–95% of the cases. S-SFT has an intermediate malignant potential with a low risk of metastasis. Some studies have investigated the prognostic role of previously described molecular markers, without, however, obtaining conclusive results; the aforementioned prognostic criteria have never been explored in B-SFT [13–16]. Most S-SFTs are clinically indolent, with an intermediate malignant potential and a low risk of metastasis, showing an overall 5- and 10-year distant metastasis (DM)-free rates of 74% and 55%, respectively. In recent times, different stratification risk models have been proposed [17–22]. The current most utilized scoring system to discriminate different risk groups for S-SFT—also related to the development of distal metastasis—is the one proposed by Demicco et al. [22], which considers patient age, mitotic activity, tumor necrosis, and size. To date, few prognostic molecular markers have been analyzed. NAB2–STAT6 chimeric transcripts, with a frequency ranging from 55 to 100% [23,24], and characterized by different breakpoints in fusion genes, might contribute to the morphologic diversity of SFT; some studies evidenced associations between specific fusion variants and different clinical features [21,25]. In addition, specific point mutations within the promoter region of telomerase reverse transcriptase (TERT)—C228T and C250T—have been recently reported in S-SFT subsets and other tumors [15,25–27]. These mutations confer enhanced TERT promoter activity and have been suggested as predictive factors to identify high-risk patients. Finally, TP53 has also been proposed as an SFTs risk factor. In particular, tumors with TP53 mutations were almost always classified as high risk [21,28]. Due to the rarity of B-SFT and taking advantage of the availability of a large and homogeneous cohort of patients, the goal of this study was to better characterize the biological behavior of this specific SFT subset located in the bone considering both the clinical, histological, and molecular features, as well as the applicability of the risk stratification model used for S-SFT.

2. Materials and Methods

The study was carried out on 24 patients affected by primary B-SFT treated at the Istituto Ortopedico Rizzoli between 1970 and 2019.

All patients were investigated, excluding history of meningeal SFT, whose metastatic bone localization could be misdiagnosed with a primary B-SFT. All cases were retrieved both from a radiological and clinical point of view through a review of medical records (anatomical site, tumor size, type of treatment, and surgical margins in the operated patients) and defined with regard to both the immuno-histochemical profile (positivity for CD34 and/or STAT6) and the molecular one (presence of the NAB2-STAT6 gene fusion products, of the C228T and C250T TERT promoter variants, and of mutations in the p53 gene). The Demicco model [22] was used for the patient’s risk stratification and the tumor size was assessed using the largest tumor dimension as a reference. All procedures were performed in accordance with the ethical standards of the Helsinki declaration. The study was approved by the ethical institutional committee on 22 July 2020 (study code: AVEC 730/2020/Oss/IOR). All analyses were completed with the help of the Statistical Package
for Social Science (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA: IBM Corp.).

2.1. Histopathology Evaluation

Hematoxylin–eosin slides of all cases were reviewed by four pathologists (A.R., M.G., M.S., A.D.T.), and the morphological diagnosis of SFT was confirmed. Tumors were scored for mitotic figures, cellularity, nuclear pleomorphism, and presence of necrosis as universal and standardized criteria defining malignancy [17,18,27]. Mitotic index was calculated per 10 high-power fields (HPFs). The presence of high cellularity areas, defined as a hypercellular tumor with areas of nuclear overlap, and the presence of high pleomorphism, determined by hyperchromatic nuclei with foci of marked pleomorphism and bizarre cells according to Demicco criteria [22], were evaluated. Necrosis was scored as absence or minimal (<10%) or positive (≥10%), based on available histological sections.

2.2. Immunohistochemistry

All paraffin-embedded tumor samples were evaluated by immunohistochemistry, as previously reported [27], with the following antibodies: CD34 (QBEnd-10; Ventana Medical Systems) and STAT6 (S-20, SC-621; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). First, 4-µm-thick tissue sections were cut, heated at 58 °C for 2 h, deparaffinized, and immunostained on a Ventana BenchMark following the manufacturer’s guidelines (Ventana Medical Systems, Tucson, AZ, USA). The detection was performed using the UltraView Universal Alkaline Phosphatase Red Detection Kit and the UltraView Universal DAB Detection Kit (Ventana Medical Systems).

2.3. DNA and RNA Isolation

Sixteen tumor samples were available for molecular analyses. DNA and RNA were isolated from 10 formalin-fixed paraffin-embedded (FFPE) and 6 frozen tissues by using a QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA) and RNeasy FFPE Tissue Kit (Qiagen), DNAzol and TRIzol (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions.

2.4. Detection of NAB2–STAT6 Fusion Variants

The 24 most frequent NAB2–STAT6 fusion variants found in S-SFT [27,29,30] were analyzed. PCR was performed by an AmpliTaq Gold 360 Master Mix (Invitrogen) using 2 µL of cDNA product as previously described [27]. PCR products were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) on an automated sequencer (ABI PRISM 3100 Genetic Analyzer 3130xl, Applied Biosystems, Foster City, CA, USA). To confirm the presence of specific NAB2–STAT6 fusion breakpoints, the sequences were aligned using the CodonCode Aligner software (https://www.codoncode.com/aligner/, accessed on 29 April 2021).

2.5. TERT Promoter Mutation Analysis

The presence of C228T and C250T mutations at the TERT promoter region was primarily evaluated by Sanger sequencing as previously described [27].

Due to the low sensitivity of Sanger sequencing in detecting somatic mutations, we analyzed the same samples by Digital PCR (QuantiStudio 3D Digital PCR System, Thermo Fisher Scientific, Waltham, MA, USA), used for rare allele detection to exclude the presence of TERT variants at low frequencies. We selected two TaqMan® probe-based assays (Hs00000093_rm, Hs00000092_rm). Polymerase chain reaction amplification was carried out on a ProFlex™ X flat PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Subsequent analysis and post-processing were performed by the QuantiStudio™ 3D AnalysisSuite™.
2.6. Analysis of p53 Mutation

To evaluate the presence of TP53 mutations, the samples were genotyped by direct sequence of all coding exons (2–11), including flanking intron-exon junctions. Sanger sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) and the ABI PRISM 3500xL Genetic Analyzer (Thermo Fisher Scientific). To evaluate the presence of potential somatic copy number variations, a Microfluidic Chip-Based Digital PCR reaction was performed using the QuantStudio™ 3D Digital PCR System (QS3D, Thermo Fisher Scientific—US). A Taqman copy number assay was selected (Hs06423639_cn) to cover approximately the central part of the gene within exon 4 (location: hg38, Chr.17:7668402-7687550). RNase P gene was chosen as a reference locus. Polymerase chain reaction amplification was carried out on a ProFlex ™ 2 × Flat PCR System (Applied Biosystems). The fluorescence data were read and analyzed using QuantStudio 3D Analysis Suite Cloud Software. Results are expressed as copies per microliter and compared as a ratio of target (FAM)/Total (FAM + VIC) expressed in percentage. In case of a regular biallelic status, we expect this value to be around 50%. The TaqMan Copy Number probe was previously tested and validated on 6 DNA with a regular biallelic status of the p53 gene (with a target/total percentage range of 48.484–50.357%), confirming the absence of CNV alterations.

2.7. Statistics

Correlations between clinical, pathological, immuno-histochemical, and molecular data were assessed using contingency tables and chi-square test. The Kaplan–Meier method was used to estimate disease-specific survival (DSS), recurrence-free survival (RFS), and metastasis-free survival (MFS) based on histopathological criteria and the presence of NAB2/STAT6 fusion variants.

MFS and DSS intervals were defined as the time between surgery and the first metastasis and death, respectively, or last follow-up available. Patients who died of other causes were excluded. By the log-rank test, differences in survival rates were assessed, considering \( p \) values < 0.05 as significant. For all analysis, was used the Statistical Package for Social Science (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA: IBM Corp.).

3. Results

3.1. Clinicopathological Evaluation

The clinical and pathological features of the 24 patients included in this study are summarized in Tables 1 and 2. The cohort is composed of 14 females (58.3%) and 10 males (41.7%) ranging from 7 to 84 years (mean 51 years). Most tumors arose in the axial skeleton (4 sacrum, 4 pubis, 2 scapula, and one lumbar vertebra), 9 in the lower extremities (6 femur, 2 tibia, and one fibula), and 4 in the upper extremities (humerus). In 5 out of 24 cases who were not feasible for surgery, only a biopsy was performed, followed by radiation therapy in two cases, chemotherapy in one, association of chemo- and radiation therapy in one, and embolization in one case. Nineteen patients underwent segmental resection or amputation with wide/radical margins in 16, intralesional margins in 2, and with marginal margins in one patient.
Table 1. Clinical features of 24 patients with a diagnosis of primary SFT of the bone.

| Patient | Age | Sex | Anatomical Site       | Tumor Size (cm) | Metastases | Surgical Procedure | Surgical Margins | DeMicco Score | Local Recurrence | Follow-Up (Months) | Status         |
|---------|-----|-----|-----------------------|-----------------|------------|-------------------|-----------------|---------------|------------------|-------------------|-----------------|
| 1       | 75  | F   | Proximal tibia        | 15              | Yes (3)    | Thigh amputation   | Wide            | High          | No               | 8                 | DOD             |
| 2       | 61  | M   | Distal femur          | 12.5            | Yes (5)    | Thigh amputation   | Wide            | High          | No               | 15                | DOD             |
| 3       | 66  | M   | Distal fibula         | 14              | Yes (0)    | Leg Amputation     | Radical         | Intermediate  | No               | 58                | DOD             |
| 4       | 71  | F   | Scapula               | 8               | Yes (0)    | Resection          | Wide            | Intermediate  | No               | 28                | DOD             |
| 5       | 84  | M   | Iliac wing            | 20              | No         | Inoperable         | NA              | Intermediate  | Yes (2)          | 2                 | DOD             |
| 6       | 52  | F   | Ileum pubic branch    | 7               | No         | Inoperable         | NA              | Low           | Yes (24)         | 56                | DOD             |
| 7       | 54  | F   | Femoral shaft         | 11              | Yes (108)  | Resection          | Wide            | Intermediate  | Yes (149)        | 168               | DOD             |
| 8       | 58  | M   | Sacrum                | 7.5             | Yes (75)   | Curettage          | Marginal        | Intermediate  | Yes (97)         | 122               | DOD             |
| 9       | 44  | F   | Distal femur          | 8.5             | Yes (66)   | Resection          | Wide            | Low           | No               | 87                | DOD             |
| 10      | 39  | F   | Proximal tibia        | 5               | No         | Resection          | Wide            | Low           | No               | 421               | NED             |
| 11      | 47  | M   | Scapula               | 6               | No         | Scapulectomy       | Wide            | Intermediate  | No               | 96                | DOC             |
| 12      | 44  | M   | Sacrum                | 7               | No         | Inoperable         | NA              | Low           | No               | 73                | DOD             |
| 13      | 50  | F   | Proximal humerus       | 16              | Yes (30)   | ISTA              | Radical         | Intermediate  | No               | 361               | NED             |
| 14      | 58  | M   | Ischiium pubic branch | 8               | No         | Resection          | Wide            | Low           | No               | 0                 | DOC             |
| 15      | 61  | F   | Iliac wing            | 8               | Yes (84)   | Resection          | Intralesional   | Low           | No               | 137               | DOD             |
| 16      | 27  | F   | Distal femur          | 17              | No         | IIAA              | Intralesional   | Intermediate  | No               | 495               | NED             |
| 17      | 32  | F   | Sacrum                | 15              | No         | Inoperable         | NA              | High          | No               | 41                | DOD             |
| 18      | 54  | M   | Sacrum                | 10              | No         | Resection          | Wide            | Low           | No               | 67                | NED             |
| 19      | 49  | M   | Proximal humerus       | 19              | No         | ISTA              | Radical         | High          | No               | 92                | DOC             |
| 20      | 31  | F   | 4th lumbar vertebra   | 8               | Yes (38)   | Vertebrectomy      | Wide            | Low           | No               | 66                | DOD             |
| 21      | 21  | F   | Proximal humerus       | 9.5             | Yes (72)   | Resection          | Wide            | Intermediate  | Yes (72)         | 72                | AWD             |
| 22      | 7   | F   | Humeral shaft         | 11              | No         | Inoperable         | NA              | Intermediate  | No               | 196               | NED             |
| 23      | 60  | F   | Proximal femur        | 7.3             | Yes (0)    | Resection          | Wide            | Intermediate  | No               | 21                | DOD             |
| 24      | 69  | M   | Femoral shaft         | 10.5            | No         | Resection          | Wide            | High          | No               | 18                | NED             |

Legend: F: female; M: male; ISTA, interscapulothoracic amputation; IIAA, interileoabdominal amputation; NA, not applicable; AWD, Alive with disease; NED, non-evidence of disease; DOD, dead of disease; DOC, dead of other causes.
Table 2. Histopathological and molecular features of SFT patients.

| Patient | Mitotic Count (X10 HPF) | Necrosis (≥10%) | STAT6 | CD34 | TERT Mutation | NAB2-STAT6 Fusion | P53 Variants (Variant Type) | Grade of Malignancy |
|---------|-------------------------|-----------------|-------|------|---------------|-------------------|---------------------------|------------------|
| 1       | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | NA                | yes (nonsense)            | HIGH             |
| 2       | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX17          | yes (CNV deletion)        | HIGH             |
| 3       | <4                      | Yes             | Pos   | Pos  | C250C/C228C   | NA                | NA                        | LOW              |
| 4       | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | NA                | NA                        | HIGH             |
| 5       | <4                      | No              | Pos   | Pos  | NA            | NA                | NA                        | LOW              |
| 6       | <4                      | No              | Pos   | Pos  | NA            | NA                | NA                        | LOW              |
| 7       | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX2-EX2           | yes (CNV deletion)        | HIGH             |
| 8       | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX16          | NA                        | HIGH             |
| 9       | <4                      | No              | Pos   | Neg  | NA            | NA                | NA                        | LOW              |
| 10      | ≥4                      | No              | Pos   | Pos  | NA            | NA                | NA                        | HIGH             |
| 11      | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | NA                | yes (splice site)         | HIGH             |
| 12      | <4                      | No              | Pos   | Pos  | C250C/C228C   | EX4-EX2           | NA                        | LOW              |
| 13      | ≥4                      | No              | Pos   | Pos  | C250C/C228C   | NA                | yes (CNV deletion)        | HIGH             |
| 14      | <4                      | No              | Pos   | Pos  | C250C/C228T   | OTHER             | no                        | LOW              |
| 15      | <4                      | No              | Pos   | Pos  | C250C/C228C   | OTHER             | yes (CNV deletion)        | LOW              |
| 16      | <4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX16/EX6-EX17 | yes (missense + CNV amplification) | LOW |
| 17      | ≥4                      | Yes             | Pos   | Pos  | NA            | NA                | NA                        | HIGH             |
| 18      | <4                      | No              | Pos   | Pos  | C250C/C228C   | EX4-EX2           | yes (CNV deletion)        | LOW              |
| 19      | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX17          | yes (CNV deletion)        | HIGH             |
| 20      | ≥4                      | No              | Pos   | Pos  | C250C/C228C   | EX6-EX17          | yes (CNV deletion)        | HIGH             |
| 21      | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX17          | yes (CNV duplication)     | HIGH             |
| 22      | ≥4                      | No              | Pos   | Pos  | NA            | NA                | NA                        | HIGH             |
| 23      | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX6-EX17          | yes (CNV deletion)        | HIGH             |
| 24      | ≥4                      | Yes             | Pos   | Pos  | C250C/C228C   | EX4-EX2           | NA                        | HIGH             |

Legend: HPF: high power fields; Pos, positive; Neg, negative; NA, not applicable; MAL, malignant.
In the group of 19 patients surgically treated, 3 patients (16%) developed local recurrence at a mean time of 106 months (range 72–149 months, median 97 months).

Twelve patients (50%) had metastasis (9 localized at lungs and 3 to bone): 3 patients had metastasis at presentation (in one case, lung; in one case, soft tissues; and in one case, both lungs and bone): chemotherapy (CT) with a combination of doxorubicin, methotrexate, cisplatin, and ifosfamide was given to the two patients with lung metastasis at presentation. The other 9 (37.5%) patients developed metastasis at a mean time of 53 months (range 3–108 months).

Nine patients with localized disease received chemotherapy with a combination of doxorubicin, methotrexate, cisplatin, and ifosfamide (eight adjuvant and one neoadjuvant chemotherapy) whereas four patients underwent radiation therapy (two adjuvant radiation 185 and two for palliation). One patient underwent selective arterial embolization with palliative intent.

The mean follow-up was 112 months (0–495), median 69 months. At the last follow-up, 14 patients out of 24 were dead of disease (DOD), 3 dead of other causes (DOC), one alive with metastatic disease (AWD), and 6 alive without evidence of disease (NED). Radiologically, all cases were lytic, with areas of sclerosis in two cases. Mean tumor size was 10.87 cm (range 5–20 cm); in 13 cases, it was ≤10 cm while in the other 11 cases, it was >10 cm (Table 1).

3.2. Histopathological and Immunohistochemical Features

From a histopathological point of view, 15 cases showed more than 4 mitotic figures per 10 HPF and were associated with high cellularity, cytologic atypia, and >10% of necrosis, defining high-grade tumors (Figure 1, Table 2). CD34 and STAT6 immunopositivity was observed in 95% (23/24) and in 100% (24/24) of cases, respectively (Figure 2).

Figure 1. Solitary fibrous tumor: A spindle cell proliferation showing hemangiopericytoma-like blood vessels is seen (Hematoxylin &Eosin, original magnification, ×100).
According to Demicco score [22], 8 patients (33%) were classified in the low-risk group, 11 (46%) in the intermediate-risk group, and 5 (21%) in the high-risk group (Table 1).

Two of the nine patients who developed distant metastasis belonged to the low-risk groups, five to the intermediate-risk group, while two patients belonged to the high-risk group. The three patients with metastasis at presentation were equally distributed in the three risk groups.

3.3. NAB2–STAT6 Fusion Variants

The analysis of fusion transcripts identified NAB2–STAT6 fusion variants in 10 out of 12 (83.3%) samples (Table 2). In two cases, no variant was found. Considering the 24 types of fusion variants evaluated, 2 breakpoints were detected with a higher frequency: NAB2exon6—STAT6exon17 (4 cases) and NAB2exon4-STAT6exon2 (3 cases), followed by the breakpoint NAB2exon6—STAT6exon16, NAB2exon2—STAT6exon2 and NAB2exon6-STAT6exon16/NAB2exon6—STAT6exon17 in one case (Table 2). Regarding the Demicco score risk, the NABex6-STAT6ex17 fusion variant was present only in high- and intermediate-risk patients, even if NAB2-STAT6 fusion variants and Demicco score risk were not significantly correlated (p = 0.25).

3.4. TERT Promoter Mutations: C228T and C250T

The wild-type C250C genotype was shown in all 16 samples while no C250T mutations were detected. In only one DNA sample, a heterozygous C228T substitution was detected. The only patient presenting this variant died one day after surgery due to complications; therefore, it was not possible to evaluate its prognostic role (Table 2).

3.5. p53 Mutations

Overall, we detected p53 genetic alterations in 11 samples (Table 2). Three samples presented point mutations: a nonsense heterozygous variant (p.Gln165*) was detected in patient 1; a missense heterozygous variants (p.Ala63Val), already described as a variant of uncertain significance (VUS), was detected in patient 16; and a homozygous splice site
alteration (c.375 + 1G > A) was observed in patient 11. All samples except two (1 and 14) showed the presence of a copy number variation (CNV) involving at least exon 4 of p53. In detail, CNV deletions were detected in patient 2, 7, 13, 15, 18, 19, and 23 whereas CNV amplifications were detected in patient 16 and 21.

3.6. Correlations between Clinicopathological, Immunohistochemical, and Molecular Data

Regarding the entire population of study (24 cases), 5- and 10-year DSS were respectively 64% and 42%, whereas on the localized tumor, 5- and 10-year disease-related-specific DSS were respectively 80% and 60%. As expected, localized and surgically treated patients (16 out of 24, 66%) showed a better 5-year DSS than metastatic ones (74% vs. 33%) (Figure 3).

Table 3 summarizes the results of the Kaplan–Meier survival analysis of the clinicopathological variables (histological grade, tumor size, age, mitosis, necrosis, Demicco score risk). Stratification by tumor size did not correlate with DSS either for localized patients (p = 0.54) or for the whole series (p = 0.44). However, the only patient with tumor size <5 cm was alive at follow up (Table 3). Stratification based on mitotic count was carried out (A ≤ 1 mitosis, B = 1–3 mitosis, and C ≥ 4); no correlation was found in terms of DSS at the 5- and 10-year follow up either for the whole series (p = 0.54) or for patients with localized disease (p = 0.33) (Table 3).

No significant differences in terms of DSS were found between the different variables analyzed by univariate analysis. Of interest, DSS in patients aged <55 and ≥55 years was found to be almost near statistical significance (p = 0.06), confirming a better prognosis in younger patients. In line with the malignancy histological criteria, none of the NAB2-STAT6 fusion variants detected were significantly correlated to DSS both in all 24 cases (p = 0.72) and in 16 localized cases (p = 0.57). In localized patients, Exon6 was involved in 2 cases out of 5 while other fusion variants (Exon2, Exon4, Other) were detectable in 3 cases out of 6; no significant correlation (p = 0.68) in terms of DSS was observed at the 5- and 10-year follow up (80% vs. 40% and 100% vs. 67%, respectively). P53 variants were assessed in 12 cases: 11 (91.6%) cases showed variation while in one case, no alteration was found. Since few
cases were analyzed, no statistical analysis was done; however, tumors with p53 mutations were classified as follows: two ‘low-risk’, three ‘high-risk’, and six ‘intermediate-risk’ cases. Further, 5- and 10-year DSS in the mutated patient was 73% and 54%, respectively, with a mean follow up of 139 months (range 8–495).

Table 3. Disease-specific survival (DSS) analysis related to clinicopathological parameters.

| Variables          | Disease Specific Survival (24 pts) | Localized Disease * (16 pts) |
|--------------------|-----------------------------------|-----------------------------|
|                    | 5 Years-DSS  | 10 Years-DSS  | p-Value  | 5 Years-DSS  | 10 Years-DSS  | p-Value  |
| Histological Grade| Low    | 62%   | 31%  | 0.52 | 100%  | 67%  | 0.84 |
|                    | High   | 65%   | 58%  | 82%  | 71%  |
| Size               | (A) 0–4.99 cm | 100% | 100% | 0.44 | 100% | 100% | 0.54 |
|                    | (B) 5–9.99 cm | 70% | 36%  | 87%  | 45%  |
|                    | (C)10–14.99 cm | 62% | 62%  | 80%  | 80%  |
|                    | (D) >15  | 50%   | 50%  | 50%  |
| Age                | <55 years | 86%   | 27%  | 0.06 | 100% | 77%  | 0.15 |
|                    | ≥55 years | 61%   | 27%  | 100% | 60%  |
| Mitosis            | (A) <1  | 60%   | 30%  | 0.54 | 60%  | 30%  | 0.33 |
|                    | (B) 1–3 | 66%   | 33%  | 100% | 50%  |
|                    | (C) ≥4  | 65%   | 58%  | 76%  | 68%  |
| Necrosis           | <10%   | 80%   | 47%  | 0.66 | 100% | 62%  | 0.95 |
|                    | ≥10%   | 51%   | 51%  | 78%  | 78%  |
| Gene Fusion        | Exon6  | 80%   | 40%  | 0.68 |
|                    | Other  | 100%  | 67%  |
| Demicco Score Risk| High   | 54%   | 54%  | 0.43 |
|                    | Intermediate | 72% | 46%  |
|                    | Low    | 64%   | 28%  |

* Surgically treated patients; DSS: disease-specific survival.

The MFS was found to be about 72% at 5 years and 27% at 10 years, as 9 out of 16 patients developed distant metastasis after a mean time of 53 months, whereas the RFS was found to be 100% at 5 years and 75% at 10 years, respectively, as 3 patients out of 16 developed local recurrence after a mean time of 106 months. No significant differences in terms of MFS and of RFS were found between the different variables analyzed by univariate analysis.

Of interest was finding that no local recurrence occurred in patients considered to be low-grade malignancy. In particular, 10-year RFS was 64% for high-grade patients against 100% in low-grade patients. Nevertheless, the p value obtained was not significant (p = 0.19), probably due to the limited number of patients, which could represent a bias.
4. Discussion

Primary B-SFT represents an extremely rare entity and to date any correlations between histopathological, immuno-histochemical, and molecular features and DSS have not yet been determined due to the lack of sufficiently numerous cases reported. Despite the rarity of this pathology, this is extremely important in order to stratify patients in terms of risk of relapse and distant metastasis and thus define the best treatment and surveillance strategies. To the best of our knowledge, the present study reports the clinical, histopathological, and molecular characteristics of the largest series reported in the literature. The primary aim of this work was to find any clinical and molecular prognostic factors and to compare them with those currently used for S-SFT [27], evaluating the possibility of a different behavior between SFT originating from the bone and from soft tissue, even if they share the same histology. Secondly, we applied the risk stratification system proposed by Demicco et al. in 2017 [22] to our selected series of 16 patients with resectable and localized primary B-SFT at onset, in order to understand whether this system, already evaluated by us previously on patients affected by S-SFT of the extremities, was able to correctly predict the risk of local and distant metastatic relapse even in the case B-SFT.

Despite the fact that SFTs of the bone and of soft tissue share the same morphological features, the data obtained in this series of the B-SFT did not confirm those already obtained by us on the S-SFT series, comparable to those available for other cases reported in the literature [14,15,18,22,24,29].

In particular, no correlations emerged between DSS, RFS, and MFS with clinicopathological variables (histological grade, tumor size, age, mitosis, necrosis, Demicco score risk), unlike what was reported by Gold and Barthelmess [14,25], and molecular features (TERT promoter mutations [14,21,25,29] and NAB2-STAT6 fusion transcripts variants). These last results appear to be in line with those reported by Machado and Bianchi [21,27]. Data of interest was the absence of local recurrence in all low-risk patients (according to Demicco scoring system), although without evidence of statistical correlation.

TERT promoter mutation in a heterozygous state (C250C/C228T) was only found in one case out of 16. Unfortunately, the patient died the day after surgery due to complications, preventing assessment of the possibility of any correlations with this mutation. These data differ markedly from those obtained by Gold, Machado, and Barthelmess [14,21,25] and from those in the case series of S-SFT of the extremities presented by Bianchi and collaborators, in which the frequency of mutations of the promoter of TERT was found to be nearly 50% and 23.7%, respectively. In particular, all three metastatic patients of our previous study presented C228T site mutation in a homozygous state [29].

Considering p53, almost all evaluated samples (91.6%) showed a genetic variant, different from what has been reported in the literature [21]. Despite the limited number of samples, 9 of the 11 tumors with p53 mutations were classified as ‘high’ or ‘intermediate’, thus confirming results detailed in a previous study [21]. Further studies will be required to evaluate the inclusion of p53 genetic status in the risk stratification system. Regarding NAB2-STAT6 fusion transcript variants, the most frequently encountered was NAB2ex6-STAT6ex17 (4 out of 12 cases), followed by NAB2ex4-STAT6ex2 in 3 cases, NAB2ex2-STAT6ex2 in one case, NAB2ex6-STAT6ex16/NAB2ex6-STAT6ex17 in one case, and NAB2ex6-STAT6ex16 in another. In two cases, there was evidence of different breakpoints from the 24 most frequently evaluated, which were therefore encoded as the other. In contrast, in our S-SFT series, the most frequently reported variants were NAB2ex6-STAT6ex17, NAB2ex6-STAT6ex2, and NAB2ex4-STAT6ex4 [27]. In both series, no statistically significant correlations emerged between the different fusion variants and the oncological outcome, different from Barthelmess and Tai, who reported a better prognosis for NAB2ex4-STAT6ex2 variants associated with a lower mitotic count and relapse rate [25,29]. However, there was a tendency for the NAB2ex6-STAT6ex17 fusion variants to be associated with high- and intermediate-risk neoplasms according to the Demicco system [22]; however, this did not result in statistically significant values (p = 0.25).
Among the limitations of this study, first, the population under study was small due to the extreme rarity of this pathology. Furthermore, there was a lack of uniformity regarding the type of treatment of the cases treated, because of the long period evaluated, during which the therapeutic approaches changed: most of the non-operated patients date back to the first decades of this period, while over the years, surgical treatments have gradually become more and more conservative and have been associated with adjuvant chemotherapy, and adjuvant or palliative radiation therapy in some cases. It is important to underline that ancillary genetic investigations, such as FISH and RT-PCR, are not yet of practical use in molecular diagnostics and are not always feasible in all cases because of the decalcification process that occurs on bone samples.

5. Conclusions

In conclusion, no correlation emerged between Demicco’s risk assessment criteria and clinical behavior as evidenced for the S-SFT. In fact, the clinicopathological criteria of malignancy devised for SFT of soft tissues failed to predict outcomes in primary SFT of the bone. Further validation on more numerous as well as more homogeneous samples is necessary to validate some molecular differences between primitive SFT of the bone with respect to that of soft tissues and to evaluate the eventual prognostic implications.

Author Contributions: Conceptualization, A.P.D.T. and M.G.; methodology, E.P., L.P., D.L., G.B. and M.S.; software, G.B.; validation, A.R.; resources, K.S., C.F., L.S. and M.G.; data curation, I.B., D.L., G.B. and A.R.; writing—original draft preparation, D.L. and G.B.; writing—review and editing, A.R., L.P. and E.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Area Vasta Emilia Centro della Regione Emilia-Romagna (protocol code: AVEC 730/2020/Oss/IOR and date of approval 22 July 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data available on request due to restrictions e.g., privacy or ethical.

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Demicco, E.G.; Fritchie, K.J.; Han, A. Solitary fibrous tumor. In WHO Classification of Tumours 5th Edition: Soft Tissue and Bone Tumours; WHO Classification of Tumours Editorial Board, Ed.; IARC Press: Lyon, France, 2020; Volume 5, pp. 104–108.
2. Klemperer, P.; Rabin, C.B. Primary neoplasms of the pleura. Arch. Pathol. 1931, 11, 385–412.
3. Picci, P.; Manfrini, M.; Donati, D.M.; Gambarotti, M.; Righi, A.; Vanel, D.; Dei Tos, A.P. Diagnosis of Musculoskeletal Tumors and Tumor-Like Conditions. Clinical, Radiological and Histological Correlations—The Rizzoli Case Archive, 2nd ed.; Springer: Cham, Switzerland, 2020; pp. 3–11.
4. Verbeke, S.L.; Fletcher, C.D.; Alberghini, M.; Daugaard, S.; Flanagan, A.M.; Parratt, T.; Kroon, H.M.; Hogendoorn, P.; Bovée, J.V. A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone. Am. J. Surg. Pathol. 2010, 34, 777–783. [CrossRef]
5. Dei Tos, A.P.; Righi, A.; Gambarotti, M.; Vanel, D.; Ferrari, C.; Benini, S.; Ferrari, S.; Picci, P. Reappraisal of primary spindle/pleomorphic sarcoma of bone. Mod. Pathol. 2014, 27, 15A.
6. Fletcher, C.D. Haemangiopericytoma- A dying breed? Reappraisal of an ‘entity’ and its variants: A hypothesis. Curr. Diagn. Pathol. 1994, 1, 19–23. [CrossRef]
7. Fletcher, C.D. The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathology 2006, 48, 3–12. [CrossRef]
8. Coca-Pelaz, A.; Llorente-Pendás, J.L.; Vivanco-Allende, B.; Suarez-Nieto, C. Solitary fibrous tumor of the petrous bone: A successful treatment option. Acta Oto-Laryngol. 2011, 131, 1349–1352. [CrossRef]
9. Ge, X.; Liao, J.; Choo, R.J.; Yan, J.; Zhang, J. Solitary fibrous tumor of the ilium. Medicine 2017, 96, e9355. [CrossRef]
10. Suarez-Zamora, D.A.; Rodriguez-Urrego, P.A.; Soto-Montoya, C.; Rivero-Rapalino, O.; Palau-Lazaro, M.A. Malignant Solitary Fibrous Tumor of the Humerus: A Case Report of an Extremely Rare Primary Bone Tumor. Int. J. Surg. Pathol. 2018, 26, 772–776. [CrossRef] [PubMed]
11. Jia, C.; Crim, J.; Everski, A.; Layfield, L.J. Solitary fibrous tumor of bone developing lung metastases on long-term follow-up. Skelet. Radiol. 2020, 49, 1865–1871. [CrossRef] [PubMed]
12. Sbaragli, M.; Righi, A.; Gambardelli, M.; Vanel, D.; Picci, P.; Tos, A.P.D. Soft Tissue Tumours Rarely Presenting Primary in Bone; Diagnostic Pitfalls. Surg. Pathol. Clin. 2017, 10, 705–730. [CrossRef] [PubMed]
13. England, D.M.; Hochholzer, L.; McCarthy, M.J. Localized Benign and Malignant Fibrous Tumors of the Pleura. Am. J. Surg. Pathol. 1989, 13, 640–658. [CrossRef] [PubMed]
14. Gold, J.S.; Antonescu, C.R.; Hajdu, C.; Ferrone, C.R.; Hussain, M.; Lewis, J.J.; Brennan, M.F.; Coit, D.G. Clinicopathologic correlates of solitary fibrous tumors. Cancer 2002, 94, 1057–1068. [CrossRef] [PubMed]
15. Gholami, S.; Cassidy, M.R.; Kirane, A.; Kuk, D.; Zanchelli, B.; Antonescu, C.R.; Singer, S.; Brennan, M. Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Ann. Surg. Oncol. 2017, 24, 3865–3871. [CrossRef] [PubMed]
16. Kim, J.M.; Choi, Y.-L.; Kim, Y.J.; Park, H.K.; Kima, J.M.; Choia, Y.-L.; Parka, H.K. Comparison and evaluation of risk factors for meningeal, pleural, and extrapleural solitary fibrous tumor: A clinicopathological study of 92 cases confirmed by STAT6 immunohistochemical staining. Pathol. Res. Pract. 2017, 213, 619–625. [CrossRef]
17. Doyle, L.A.; Fletcher, C.D.M. Predicting behavior of solitary fibrous tumor: Are we getting closer to more accurate risk assessment? Ann. Surg. Oncol. 2013, 20, 4055–4056. [CrossRef]
18. Demico, E.G.; Park, M.S.; Araujo, D.M.; Fox, P.S.; Bassett, R.L.; E Pollock, R.; Lazar, A.J.; Wang, W.-L. Solitary fibrous tumor: A clinicopathological study of 110 cases and proposed risk assessment model. Mod. Pathol. 2012, 25, 1298–1306. [CrossRef]
19. Pasquali, S.; Gronchi, A.; Strauss, D.; Bonvalot, S.; Jey, L.; Stanči, S.; Hayes, A.; Honore, C.; Collini, P.; Renne, S.L.; et al. Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study. Eur. J. Surg. Oncol. (EJSO) 2016, 42, 1064–1070. [CrossRef]
20. Salas, S.; Resseguyer, N.; Blay, J.Y.; Le Cesne, A.; Italiano, A.; Chevreau, C.; Rosset, P.; Isambert, N.; Soulée, P.; Cupissol, D.; et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: Construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann. Oncol. 2017, 28, 1779–1787. [CrossRef]
21. Machado, I.; Morales, G.N.; Cruz, J.; Lavernia, J.; Giner, F.; Navarro, S.; Ferrandez, A.; Llombart-Bosch, A. Solitary fibrous tumor: A case series identifying pathological adverse factors—implications for risk stratification and classification. Virchows Arch. 2019, 476, 597–607. [CrossRef]
22. Demico, E.G.; Wagner, M.J.; Maki, R.G.; Gupta, V.; Iofin, I.; Lazar, A.J.; Wang, W.-L. Risk assessment in solitary fibrous tumors: Validation and refinement of a risk stratification model. Mod. Pathol. 2017, 30, 1433–1442. [CrossRef] [PubMed]
23. Chmielecki, J.; Crago, A.M.; Rosenberg, M.; O’Connor, R.; Walker, S.R.; Ambrogio, L.; Auclair, D.; McKenna, A.; Heinrich, M.C.; Frank, D.A.; et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat. Genet. 2013, 45, 131–132. [CrossRef] [PubMed]
24. Robinson, D.R.; Wu, Y.-M.; Kalyana-Sundaram, S.; Cao, X.; Lonigro, R.J.; Sung, Y.-S.; Chen, C.-L.; Zhang, L.; Wang, R.; Su, F.; et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 2013, 45, 180–185. [CrossRef]
25. Barthelmeß, S.; Geddart, H.; Bolzte, C.; Moskalová, E.A.; Bieg, M.; Sirbu, H.; Brors, B.; Wiemann, S.; Hartmann, A.; Agaimy, A.; et al. Solitary Fibrous Tumors/Hemangiopericytomas with Different Variants of the NAB2-STAT6 Gene Fusion Are Characterized by Specific Histomorphology and Distinct Clinicopathological Features. Am. J. Pathol. 2014, 184, 1209–1218. [CrossRef] [PubMed]
26. Bahrami, A.; Lee, S.; Schaefer, I.-M.; Boland, J.M.; Patton, K.T.; Pounds, S.; Fletcher, C.D. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod. Pathol. 2016, 29, 1511–1522. [CrossRef] [PubMed]
27. Bianchi, G.; Sambri, A.; Pedrini, E.; Pazzaglia, L.; Sangiorgi, L.; Ruengwanichayakun, P.; Donati, D.; Benassi, M.S.; Righi, A. Histological and molecular features of solitary fibrous tumor of the extremities: Clinical correlation. Virchows Arch. 2020, 476, 445–454. [CrossRef]
28. Park, H.K.; Yu, D.B.; Sung, M.; Oh, E.; Kim, M.; Song, J.-Y.; Lee, M.-S.; Jung, K.; Noh, K.-W.; An, S.; et al. Molecular changes in solitary fibrous tumor progression. J. Mol. Med. 2019, 97, 1413–1425. [CrossRef]
29. Tai, H.-C.; Chuang, I.-C.; Chen, T.-C.; Li, C.-F.; Huang, S.-C.; Kao, Y.-C.; Lin, P.-C.; Tsai, J.-W.; Lan, J.; Yu, S.-C.; et al. NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod. Pathol. 2015, 28, 1324–1335. [CrossRef] [PubMed]
30. Akaïke, K.; Kurisaki-Arakawa, A.; Haru, K.; Suehara, Y.; Takagi, T.; Mitani, K.; Kaneko, K.; Yao, T.; Saito, T. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum. Pathol. 2015, 46, 347–356. [CrossRef] [PubMed]